Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.&...
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. Ma...
Last week, Novavax Inc (NASDAQ: NVAX) received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1...
The Nasdaq 100 closed higher by around 250 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell share...
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) ...
Novavax, Inc. (NASDAQ: NVAX) shares are trading lower Wednesday amid a pullback in the stock, which gained Tuesday after the FDA granted Emergency ...
Moderna, Inc (NASDAQ: MRNA) shares are trading higher Wednesday. The company announced positive data from its combination vaccine against influenza...
Novavax Inc (NASDAQ: NVAX) shares are surging Tuesday afternoon after the U.S. Food and Drug Administration (FDA) granted Emergency Use A...
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.&nbs...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...